ZAHRA: JOURNAL OF HEALTH AND MEDICAL RESEARCHVol. 3 No. 4 (2023): OKTOBER
EMPAGLIFLOZIN: TERAPI BARU UNTUK PASIEN GAGAL JANTUNG DENGAN KOMORBID DIABETES MELLITUS TIPE 2 (DMT2)
Maha Fitra ND(Program Studi Spesialis-1 Jantung dan Pembuluh Darah Fakultas Kedokteran Universitas Syiah Kuala, Indonesia)
Article Info
Publish Date 06 Jun 2023
Abstract
Type 2 diabetes mellitus (DMT2) and heart failure have a strong relationship and one clinical outcome affects the other. Recent studies have succeeded in proving the benefits of empagliflozin, an SGLT2 inhibitor class drug (second-line drug for T2DM), on the cardiovascular system. In addition to the diuretic role, the cellular mechanism of empagliflozin that is known to play a role in animals is myocardial anti-fibrosis effect.
This Journal focuses on health sciences, including preventive, promotive, curative, and rehabilitative fields, by publishing "original articles" and "review articles." The scientific scope of the Health Scientific Journal include Medical and clinical research, Public health research (health ...